Status:

NOT_YET_RECRUITING

Folic Acid Supplementation to Reduce Anemia in Extremely Preterm Infants

Lead Sponsor:

University of Calgary

Conditions:

Extreme Prematurity

Anemia of Prematurity

Eligibility:

All Genders

Phase:

NA

Brief Summary

Anemia of Prematurity (AOP) is very common in extremely preterm infants and often leads to blood transfusions. Folic acid, essential for growth and DNA synthesis, is deficient in premature infants. De...

Detailed Description

Anemia of prematurity (AOP) affects nearly all extremely preterm or extremely low birthweight (ELBW; birthweight \<1000 g) infants. AOP's development involves various factors such as exacerbation of n...

Eligibility Criteria

Inclusion

  • Infants born at \<29 weeks of gestational age admitted to Foothill Medical Centre.
  • Postnatal age 14 days.
  • On minimum enteral feeding of 100 mL/kg/day

Exclusion

  • Infants with major congenital or chromosomal anomalies
  • Infants with ongoing pulmonary or gastroenterology hemorrhage by 14 days of life.

Key Trial Info

Start Date :

June 1 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2028

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT06220461

Start Date

June 1 2024

End Date

July 31 2028

Last Update

May 9 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Foothills Medical Centre

Calgary, Alberta, Canada, T2N2T9

Folic Acid Supplementation to Reduce Anemia in Extremely Preterm Infants | DecenTrialz